• Caris Life Sciences Launches MI FOLFOXai, Improving Overall Survival by 50% for Metastatic Colorectal Cancer Patients

    First AI-powered FOLFOX predictor to guide first-line metastatic colorectal cancer treatment   IRVING, Texas, March 31, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the launch of MI FOLFOXai, the newest addition to the company’s suite of comprehensive molecular science offerings. MI FOLFOXai is an Artificial Intelligence (AI)-based predictor of response to FOLFOX chemotherapy in metastatic colorectal cancer that demonstrated approximately 50 percent improvement in overall survival across two independent validation studies. … Read More

  • Caris Life Sciences to Present at Cowen and Company 40th Annual Health Care Conference

    IRVING, Texas, Feb. 19, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that Brian Brille, Vice Chairman of the Company, will present at the Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3, 2020, at 9:30 a.m. Eastern time. The conference is being held at the Boston Marriott Copley Place, Boston.   Mr. … Read More

  • Study Shows That Caris Life Sciences’ ADAPT Biotargeting System™ Has Discovered Protein Expression Pattern Differences Between Two Prostate Cancer Patient Subpopulations

    First time findings published in Nucleic Acids Research demonstrate the ability to differentiate exosomes from cancer cell subtypes from the same tumor type offering broad potential applications in biomarker discovery   IRVING, Texas, Feb. 12, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the publication of new data in Nucleic Acids Research, illustrating that use of the Company’s proprietary ADAPT Biotargeting System™ can lead to the identification of differences in protein expression patterns between exosomes from two related prostate cancer cell lines, … Read More

  • Caris Life Sciences Appoints New Executive Medical Director

    IRVING, Texas, Feb. 11, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today Matthew Oberley, M.D., Ph.D., has been appointed Executive Medical Director.   Dr. Oberley joined Caris in August 2019 as Senior Medical Director and has functioned as a leading face for Caris’ clinical and scientific expertise in the marketplace and research community. His responsibilities have included managing the Company’s Medical Science Liaison team and helping connect key oncology research leaders across the country with the large datasets Caris has generated through the Company’s molecular profiling technology. … Read More

  • Cedars-Sinai Joins Caris Life Sciences’ Precision Oncology Alliance

    Nationally recognized center becomes 33rd member of Caris’ collaborative network focused on expanding the application of precision medicine in cancer treatment   IRVING, Texas & LOS ANGELES, Calif., Jan. 14, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that the Samuel Oschin Comprehensive Cancer Institute at Los Angeles-based Cedars-Sinai has become the 33rd member of its Precision Oncology Alliance™. … Read More